Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.57 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455793 | 1.00 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15203246 | 1.00 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL792570 | 0.99 | F10 (0.97) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL792571 | 0.99 | F10 (0.97) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Sulfuric Acid SCHEMBL793039 | 0.94 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Sulfuric Acid SCHEMBL793040 | 0.94 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Oxalic Acid SCHEMBL14861652 | 0.94 | F10 (0.88) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13737134 | 0.93 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13736179 | 0.93 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Acetic Acid SCHEMBL13738152 | 0.93 | F10 (0.86) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530233-A | Preparation method of rivaroxaban and intermediate thereof | 武汉工程大学 | 2024-08-23 | — | — | CN | claimed |
| CN-118050436-A | Method for separating and measuring potential genotoxic impurity (imidazole) in rivaroxaban intermediate by high performance liquid chromatography-mass spectrometry | 南京海辰药业股份有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-112110910-B | Method for preparing rivaroxaban intermediate and method for preparing rivaroxaban from rivaroxaban intermediate | 上海特化医药科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-115894471-A | Synthetic method of rivaroxaban | 南京工业大学 | 2023-04-04 | — | — | CN | claimed |
| CN-115825284-A | Method for separating rivaroxaban intermediate and impurities thereof and detecting content of each component | 重庆华邦制药有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-115490678-A | Preparation method of high-purity rivaroxaban | 浙江苏泊尔制药有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-115403555-A | Synthetic method of rivaroxaban intermediate 5-chlorothiophene-2-carboxylic acid | 上海茂晟康慧科技有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-111983055-B | Method for separating and measuring rivaroxaban intermediate related substances by using HPLC (high performance liquid chromatography) | 安徽联创生物医药股份有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-110551111-B | Preparation method of rivaroxaban intermediate | 上海海翔医药科技发展有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-216347362-U | A vacuum drying oven for rivaroxaban midbody | 上海汇伦湖北制药有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-07-04 | — | — | US | claimed |
| WO-2013027225-A1 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2013-02-28 | — | — | WO | claimed |
| WO-2012156983-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENECARBOXAMIDE | SYMED LABS LIMITED (IN) | 2012-11-22 | — | — | WO | claimed |
| WO-2012153155-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGIS GYÓGYSZERGYÁR NYILVÃNOSAN MÜKÖDÖ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-11-15 | — | — | WO | claimed |
| WO-2012035057-A2 | PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE | MEDICHEM S.A. (ES) | 2012-03-22 | — | — | WO | claimed |
| WO-2012032533-A2 | PROCESSES FOR THE PREPARATION OF 4-{4-[5(S)-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL} MORPHOLIN-3-ONE | SYMED LABS LIMITED (IN) | 2012-03-15 | — | — | WO | claimed |
| EP-2388260-A1 | Method for producing a blood coagulation factor inhibitor | Archimica GmbH (DE) | 2011-11-23 | — | — | EP | claimed |
| US-8038533-B2 | Game system using parent game machine and child game machine | NINTENDO CO., LTD. (JP) | 2011-10-18 | — | — | US | claimed |
| US-7351823-B2 | Preparation process | BAYER HEALTHCARE AG (DE) | 2008-04-01 | — | — | US | claimed |
| US-20050182055-A1 | 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide formed by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one hydrochloride with 5-chlorothiophene-2-carbonyl chloride | BAYER HEALTHCARE AG (DE) | 2005-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172554-A1 | PROCESSES FOR THE PREPARATION OF 4-MORPHOLIN-3-ONE | TYR, CYP1B1, AAAS | F10 4199/4885CYP1A2 26/4885CYP3A4 7/4885 |
| US-20050182055-A1 | 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide formed by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one hydrochloride with 5-chlorothiophene-2-carbonyl chloride | NT5C, HTR2C, HTR5A | F10 4646/4885CYP1A2 908/4885CYP3A4 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.